Neuphoria Therapeutics to Receive $15 Mln Payment from Merck

Dow Jones

02-12

By Adriano Marchese

Neuphoria Therapeutics said it expects to receive a milestone payment from Merck for the second clinical trial phase of its Alzheimer's disease dementia treatment.

The biotechnology company said Wednesday that it is expecting to receive $15 million from the pharmaceutical giant now that it has started the phase 2 clinical trial to evaluate the safety and efficacy of MK-1167.

The drug aims to enhance the activity of a certain receptor in the brain which is involved in cognitive functions like memory and learning.

Neuphoria said that the payment marks the second milestone payment in collaboration with Merck. The company has an agreement to receive $450 million in additional milestone payments for progress on multiple candidates, including MK-1167.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

February 12, 2025 07:34 ET (12:34 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2510269375"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510269375\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2510269375?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510269375","market":"sg","top_or_hot":-1,"title":"Neuphoria Therapeutics to Receive $15 Mln Payment from Merck","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Neuphoria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it expects to receive a milestone payment from Merck for the second clinical trial phase of its Alzheimer's disease dementia treatment. \n</p>\n<p>\n  The biotechnology company said Wednesday that it is expecting to receive $15 million from the pharmaceutical giant now that it has started the phase 2 clinical trial to evaluate the safety and efficacy of MK-1167. \n</p>\n<p>\n  The drug aims to enhance the activity of a certain receptor in the brain which is involved in cognitive functions like memory and learning. \n</p>\n<p>\n  Neuphoria said that the payment marks the second milestone payment in collaboration with Merck. The company has an agreement to receive $450 million in additional milestone payments for progress on multiple candidates, including MK-1167. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 12, 2025 07:34 ET (12:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Neuphoria Therapeutics to Receive $15 Mln Payment from Merck</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuphoria Therapeutics to Receive $15 Mln Payment from Merck\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-02-12 20:34</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Neuphoria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it expects to receive a milestone payment from Merck for the second clinical trial phase of its Alzheimer's disease dementia treatment. \n</p>\n<p>\n  The biotechnology company said Wednesday that it is expecting to receive $15 million from the pharmaceutical giant now that it has started the phase 2 clinical trial to evaluate the safety and efficacy of MK-1167. \n</p>\n<p>\n  The drug aims to enhance the activity of a certain receptor in the brain which is involved in cognitive functions like memory and learning. \n</p>\n<p>\n  Neuphoria said that the payment marks the second milestone payment in collaboration with Merck. The company has an agreement to receive $450 million in additional milestone payments for progress on multiple candidates, including MK-1167. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 12, 2025 07:34 ET (12:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1035773651.USD","symbol_name":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2510269375","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510269375","pubTimestamp":1739363640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Neuphoria Therapeutics said it expects to receive a milestone payment from Merck for the second clinical trial phase of its Alzheimer's disease dementia treatment.The biotechnology company said Wednesday that it is expecting to receive $15 million from the pharmaceutical giant now that it has started the phase 2 clinical trial to evaluate the safety and efficacy of MK-1167.The drug aims to enhance the activity of a certain receptor in the brain which is involved in cognitive functions like memory and learning.Neuphoria said that the payment marks the second milestone payment in collaboration with Merck. The company has an agreement to receive $450 million in additional milestone payments for progress on multiple candidates, including MK-1167.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LENZ":"Therapeutics","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0861579265.USD":"联博低波幅策略股票基金A","LU0238689110.USD":"贝莱德环球动力股票基金","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4516":"特朗普概念","SG9999001176.USD":"United Global Healthcare Acc USD","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","NEUP":"Neuphoria Therapeutics Inc","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","MRK":"默沙东","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4559":"巴菲特持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist"},"translate_title":"Neuphoria Therapeutics将收到默克公司1500万美元的付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"MRK":1,"NEUP":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Neuphoria Therapeutics said it expects to receive a milestone payment from Merck for the second clinical trial phase of its Alzheimer's disease dementia treatment. \n\n\n  The biotechnology company said Wednesday that it is expecting to receive $15 million from the pharmaceutical giant now that it has started the phase 2 clinical trial to evaluate the safety and efficacy of MK-1167. \n\n\n  The drug aims to enhance the activity of a certain receptor in the brain which is involved in cognitive functions like memory and learning. \n\n\n  Neuphoria said that the payment marks the second milestone payment in collaboration with Merck. The company has an agreement to receive $450 million in additional milestone payments for progress on multiple candidates, including MK-1167. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 12, 2025 07:34 ET (12:34 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}